MX2023001929A - Derivados de 1h-pirrol[3,2-c]piridina y 1h-pirrol[2,3-c]piridina como inhibidores del receptor tipo troll 9 (tlr9) para el tratamiento de fibrosis. - Google Patents
Derivados de 1h-pirrol[3,2-c]piridina y 1h-pirrol[2,3-c]piridina como inhibidores del receptor tipo troll 9 (tlr9) para el tratamiento de fibrosis.Info
- Publication number
- MX2023001929A MX2023001929A MX2023001929A MX2023001929A MX2023001929A MX 2023001929 A MX2023001929 A MX 2023001929A MX 2023001929 A MX2023001929 A MX 2023001929A MX 2023001929 A MX2023001929 A MX 2023001929A MX 2023001929 A MX2023001929 A MX 2023001929A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- pyrrolo
- pyridine
- treatment
- tlr9
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067465P | 2020-08-19 | 2020-08-19 | |
| PCT/US2021/046434 WO2022040267A1 (en) | 2020-08-19 | 2021-08-18 | 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001929A true MX2023001929A (es) | 2023-03-09 |
Family
ID=77711459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001929A MX2023001929A (es) | 2020-08-19 | 2021-08-18 | Derivados de 1h-pirrol[3,2-c]piridina y 1h-pirrol[2,3-c]piridina como inhibidores del receptor tipo troll 9 (tlr9) para el tratamiento de fibrosis. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12590091B2 (enExample) |
| EP (1) | EP4200298B1 (enExample) |
| JP (1) | JP2023538608A (enExample) |
| KR (1) | KR20230053646A (enExample) |
| CN (1) | CN115867549A (enExample) |
| AR (1) | AR123285A1 (enExample) |
| AU (1) | AU2021328577A1 (enExample) |
| BR (1) | BR112023002646A2 (enExample) |
| CA (1) | CA3189826A1 (enExample) |
| ES (1) | ES3034264T3 (enExample) |
| IL (1) | IL300643A (enExample) |
| MX (1) | MX2023001929A (enExample) |
| TW (1) | TW202214233A (enExample) |
| WO (1) | WO2022040267A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| EP4479135A1 (en) * | 2022-02-18 | 2024-12-25 | Bristol-Myers Squibb Company | Substituted imidazopyridinyl compounds useful as inhibitors of tlr9 |
| KR20250109202A (ko) * | 2022-11-10 | 2025-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr9의 억제제로서 유용한 치환된 벤즈이미다졸 화합물 |
| CN120152957A (zh) * | 2022-11-10 | 2025-06-13 | 百时美施贵宝公司 | 用作tlr9抑制剂的经取代的喹诺酮 |
| WO2024163380A1 (en) * | 2023-01-31 | 2024-08-08 | Bristol-Myers Squibb Company | Substituted benzimidazole compounds useful as inhibitors of tlr9 |
| TW202504599A (zh) | 2023-06-30 | 2025-02-01 | 美商必治妥美雅史谷比公司 | Kras抑制劑 |
| WO2026039512A1 (en) | 2024-08-14 | 2026-02-19 | Bristol-Myers Squibb Company | Kras inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| GB0602178D0 (en) | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| US20130158066A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 4-azaindole inhibitors of crac |
| US20130158049A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 7-azaindole inhibitors of crac |
| WO2013156431A1 (en) | 2012-04-17 | 2013-10-24 | Syngenta Participations Ag | Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| CA2933466A1 (en) * | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| EP3538513A1 (en) | 2016-11-11 | 2019-09-18 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| US11399542B2 (en) | 2017-07-05 | 2022-08-02 | Syngenta Participations Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
| ES2921020T3 (es) | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
| WO2019099336A1 (en) | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
| AU2018386201A1 (en) | 2017-12-15 | 2020-07-30 | Bristol-Myers Squibb Company | Substituted indole ether compounds |
| JP7289301B2 (ja) | 2017-12-18 | 2023-06-09 | ブリストル－マイヤーズ スクイブ カンパニー | ４－アザインドール化合物 |
| SG11202005704RA (en) * | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | 6-azaindole compounds |
| US11878975B2 (en) | 2017-12-19 | 2024-01-23 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
| CN111511730B (zh) | 2017-12-19 | 2023-07-25 | 百时美施贵宝公司 | 可用作tlr抑制剂的被酰胺取代的吲哚化合物 |
| CA3085937A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| AU2019319835A1 (en) | 2018-08-08 | 2021-03-25 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of PAD enzymes |
-
2021
- 2021-08-18 AU AU2021328577A patent/AU2021328577A1/en not_active Abandoned
- 2021-08-18 US US18/042,069 patent/US12590091B2/en active Active
- 2021-08-18 IL IL300643A patent/IL300643A/en unknown
- 2021-08-18 TW TW110130428A patent/TW202214233A/zh unknown
- 2021-08-18 ES ES21769261T patent/ES3034264T3/es active Active
- 2021-08-18 AR ARP210102329A patent/AR123285A1/es not_active Application Discontinuation
- 2021-08-18 MX MX2023001929A patent/MX2023001929A/es unknown
- 2021-08-18 JP JP2023512162A patent/JP2023538608A/ja active Pending
- 2021-08-18 WO PCT/US2021/046434 patent/WO2022040267A1/en not_active Ceased
- 2021-08-18 CN CN202180050340.3A patent/CN115867549A/zh active Pending
- 2021-08-18 KR KR1020237009022A patent/KR20230053646A/ko active Pending
- 2021-08-18 BR BR112023002646A patent/BR112023002646A2/pt not_active Application Discontinuation
- 2021-08-18 CA CA3189826A patent/CA3189826A1/en active Pending
- 2021-08-18 EP EP21769261.5A patent/EP4200298B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12590091B2 (en) | 2026-03-31 |
| TW202214233A (zh) | 2022-04-16 |
| WO2022040267A1 (en) | 2022-02-24 |
| BR112023002646A2 (pt) | 2023-04-04 |
| KR20230053646A (ko) | 2023-04-21 |
| CN115867549A (zh) | 2023-03-28 |
| US20230312565A1 (en) | 2023-10-05 |
| AU2021328577A1 (en) | 2023-03-23 |
| CA3189826A1 (en) | 2022-02-24 |
| AR123285A1 (es) | 2022-11-16 |
| EP4200298B1 (en) | 2025-05-21 |
| ES3034264T3 (en) | 2025-08-14 |
| IL300643A (en) | 2023-04-01 |
| EP4200298A1 (en) | 2023-06-28 |
| JP2023538608A (ja) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001884A (es) | Derivados de 1h-benzo[d]imidazol como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de fibrosis. | |
| MX2023001885A (es) | Derivados de imidazo[1,2-a]piridina y [1,2,4]triazolo[1,5-a]piridi na como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de la fibrosis. | |
| PH12017501384A1 (en) | Pharmaceutical compositions for combination therapy | |
| JP2016512202A5 (enExample) | ||
| MX2024007058A (es) | Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer. | |
| IN2013MU01468A (enExample) | ||
| JP2016510769A5 (enExample) | ||
| MX379424B (es) | Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis. | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| JOP20210056A1 (ar) | مركبات حمض أميني وطرق استخدامها | |
| MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
| PH12013501855A1 (en) | Combination therapies for hematologic malignancies | |
| JP2014526513A5 (enExample) | ||
| WO2007111992A3 (en) | Methods and compositions for treating hypercholesterolemia and atherosclerosis | |
| WO2005073224A3 (en) | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer | |
| WO2012033792A3 (en) | Treatment of diseases | |
| MX2010006519A (es) | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. | |
| MX2023001883A (es) | Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9). | |
| EA200970933A1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| MX382960B (es) | Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica. | |
| CN107835687A (zh) | 癌症治疗 | |
| WO2008109991A8 (en) | Inhibitors of carnitine palmitoyltransferase and treating cancer | |
| WO2017123592A8 (en) | Bacteria engineered to treat disorders associated with bile salts | |
| MX2019013275A (es) | Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos. | |
| PH12022551596A1 (en) | Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same |